Trials / Completed
CompletedNCT02247310
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 498 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is important. The data storage capabilities of the BETACONNECT device, including the automated recording of injections, will facilitate the collection of reliable data on patient's injection behavior and adherence, which should be unaffected by recall bias or reporting bias. To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using this device for 24 weeks. The study will take place in a real-life setting in Neurology centers across Europe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1b (Betaferon®, BAY 86-5046) | Patients will be treated with Betaferon |
| DEVICE | BETACONNECT | Auto-injector device to support the injection of Betaferon |
Timeline
- Start date
- 2014-10-20
- Primary completion
- 2016-07-19
- Completion
- 2016-11-08
- First posted
- 2014-09-25
- Last updated
- 2017-11-07
Locations
11 sites across 11 countries: Austria, Belgium, Bosnia and Herzegovina, Croatia, Czechia, France, Greece, Hungary, Italy, Spain, Switzerland
Source: ClinicalTrials.gov record NCT02247310. Inclusion in this directory is not an endorsement.